DelveInsight Business Research LLP

DelveInsight’s “Hypoventilation Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Hypoventilation, historical and forecasted epidemiology as well as the Hypoventilation market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. 

The Hypoventilation market report provides current treatment practices, emerging drugs, Hypoventilation market share of the individual therapies, and current and forecasted Hypoventilation market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hypoventilation treatment practices/algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Some of the key facts of the Hypoventilation Market Report:

• Enasidenib is an oral selectively allosteric inhibitor of IDH2 mutation developed by Celgene Corporation under a global exclusive license from Agios Pharmaceuticals. It shows more powerful inhibitory effects on IDH2 R172K rather than IDH1 R140Q (ORR, 53.3% vs. 35.4%; CR, 24.4% vs. 17.7%) mutation, although it has inhibitory effects on both the mutations. FDA approved enasidenib for the treatment of adult R/R AML with IDH2 mutations on 1 August 2017. The recommended oral dose is 100 mg once daily for at least 6 months or until disease progression or intolerable adverse reaction.

Key Benefits of the Report:

• The report covers the descriptive overview of Hypoventilation, explaining its causes, signs, and symptoms, pathophysiology, diagnosis, and currently available therapies

• Comprehensive insight has been provided into the Hypoventilation epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Hypoventilation is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Hypoventilation market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hypoventilation market.

Got queries? Click here to know more about the  Hypoventilation Market Landscape 

Hypoventilation Overview

Hypoventilation is breathing that is too shallow or too slow to meet the needs of the body. If a person hypoventilates, the body’s carbon dioxide level rises. This causes a buildup of acid and too little oxygen in the blood. A person with hypoventilation might feel sleepy. In patients without parenchymal lung disease, hypoxemia from high altitude, obstructive sleep apnea (OSA), and obesity hypoventilation syndrome (OHS) are important independent causes of PH by themselves, or they may contribute significantly to PH from other causes. High altitude affects a large number of individuals globally. Thus, environmental hypoxemia related to altitude may be one of the most common causes of PH worldwide.

Hypoventilation Epidemiology Insights: 

• Estimates based on rates of obesity and obstructive sleep apnea (OSA) in the community suggest 0.15 to 0.3 percent of the adult population in the United States are likely to have hyperventilation.

• The prevalence of OHS increases as body mass index (BMI) rises. In several retrospective studies among patients with OSA, the prevalence of OHS in those with a BMI of 30 to 35 kg/m2 is 8 to 12 percent, higher among those with a BMI ≥40 kg/m2 (18 to 31 percent) and those with a BMI ≥50 kg/m2 (50 percent).

Hypoventilation Epidemiological Segmentation 

• Hypoventilation market prevalent cases 

• Hypoventilation market-diagnosed cases 

• Hypoventilation market treatment cases 

Hypoventilation Market Outlook 

The Hypoventilation market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hypoventilation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

This segment gives a thorough detail of the Hypoventilation market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, the Hypoventilation market in 7MM is expected to change in the study period 2019-2032.

Learn more by requesting for sample @ Hypoventilation Market Landscape

Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of  Hypoventilation Market  Market 

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Hypoventilation Market  Market  Emerging Therapies

7.  Hypoventilation Market  Market Cancer Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Appendix

10.  Hypoventilation Market  Market   Report Methodology

11.  DelveInsight Capabilities

12.  Disclaimer

13. About DelveInsight

Click here to read more about Hypoventilation Market Landscape

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/